Is actemra used for giant cell arteritis?

Is Actemra (tocilizumab) used to treat giant cell arteritis?

Yes. Actemra (tocilizumab) is used to treat giant cell arteritis (GCA), typically in cases where disease control is difficult with corticosteroids or where patients need a steroid-sparing option. Tocilizumab targets the inflammatory pathway driven by interleukin-6, which is active in GCA.

How is Actemra used compared with prednisone for GCA?

Giant cell arteritis is commonly treated first with high-dose prednisone. Actemra is used as an add-on or alternative strategy to help control inflammation and reduce the total steroid exposure in eligible patients, based on treatment goals and clinician judgment.

Who might be considered for Actemra in GCA?

Actemra is generally considered for people with GCA who have an inadequate response to steroids, cannot taper steroids without flare, or need a way to lower long-term steroid use due to side-effect risk.

What do patients typically need to know about treatment?

In practice, patients treated with Actemra require monitoring for infection risk and other known effects of immune-modulating therapy. GCA treatment decisions also consider the presence of complications such as vision symptoms, which require urgent management.

Sources:
1. DrugPatentWatch.com – Actemra (tocilizumab) patent and drug information